BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.39), Zacks reports.
BriaCell Therapeutics Price Performance
NASDAQ BCTX opened at $4.07 on Tuesday. The firm has a market capitalization of $15.10 million, a P/E ratio of -0.31 and a beta of 1.71. BriaCell Therapeutics has a 1-year low of $3.00 and a 1-year high of $45.45. The business’s 50-day simple moving average is $4.73 and its 200-day simple moving average is $9.05.
Analysts Set New Price Targets
Separately, HC Wainwright raised their price target on BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Taiwan Semiconductor Valuation: How Realistic Is the Price?
- EV Stocks and How to Profit from Them
- Microsoft’s AI Strategy Eases Analyst Concerns—Is It a Buy?
- What Makes a Stock a Good Dividend Stock?
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
